Karimah Es Sabar Sells 61,265 Shares of Capricor Therapeutics (NASDAQ:CAPR) Stock

Key Points

• Director Karimah Es Sabar sold a total of 115,000 Capricor shares (61,265 on Mar 31 at $30.17 and 53,735 on Apr 1 at $31.03), generating roughly $3.52 million, as disclosed in SEC filings.
• Capricor (CAPR) is trading around $31.62 with a market cap of about $1.82 billion; it reported a quarterly EPS of - $0.62 (missing estimates) while analysts hold a consensus "Moderate Buy" rating with an average price target of $46.09.

Capricor Therapeutics, Inc. (NASDAQ:CAPR - Get Free Report) Director Karimah Es Sabar sold 61,265 shares of the stock in a transaction dated Tuesday, March 31st. The stock was sold at an average price of $30.17, for a total transaction of $1,848,365.05. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Karimah Es Sabar also recently made the following trade(s):

• On Wednesday, April 1st, Karimah Es Sabar sold 53,735 shares of Capricor Therapeutics stock. The shares were sold at an average price of $31.03, for a total value of $1,667,397.05.

Capricor Therapeutics Price Performance

CAPR traded up $1.50 during trading hours on Thursday, hitting $31.62. 346,173 shares of the stock were exchanged, compared to its average volume of 1,371,751. The stock has a market cap of $1.82 billion, a price-to-earnings ratio of -14.08 and a beta of 0.48. The stock has a 50-day simple moving average of $27.04 and a 200-day simple moving average of $18.74. Capricor Therapeutics, Inc. has a 12 month low of $4.30 and a 12 month high of $40.37.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last released its earnings results on Thursday, March 12th. The biotechnology company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.11). Sell-side analysts expect that Capricor Therapeutics, Inc. will post -1.21 EPS for the current year.

Institutional Investors Weigh In On Capricor Therapeutics

A number of hedge funds have recently made changes to their positions in the business. Goldman Sachs Group Inc. increased its position in shares of Capricor Therapeutics by 39.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 411,141 shares of the biotechnology company's stock valued at $3,902,000 after purchasing an additional 116,373 shares during the period. Geode Capital Management LLC grew its holdings in Capricor Therapeutics by 6.8% during the second quarter. Geode Capital Management LLC now owns 963,080 shares of the biotechnology company's stock worth $9,565,000 after acquiring an additional 61,701 shares during the period. Legal & General Group Plc grew its holdings in Capricor Therapeutics by 8.4% during the second quarter. Legal & General Group Plc now owns 41,273 shares of the biotechnology company's stock worth $410,000 after acquiring an additional 3,205 shares during the period. Rhumbline Advisers raised its position in Capricor Therapeutics by 7.3% in the second quarter. Rhumbline Advisers now owns 53,450 shares of the biotechnology company's stock worth $531,000 after acquiring an additional 3,636 shares in the last quarter. Finally, Marshall Wace LLP acquired a new stake in Capricor Therapeutics in the 2nd quarter valued at about $796,000. Institutional investors own 21.68% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the company. Alliance Global Partners restated a "buy" rating on shares of Capricor Therapeutics in a research note on Wednesday, December 3rd. UBS Group set a $50.00 price target on Capricor Therapeutics in a report on Monday, December 15th. Piper Sandler restated an "overweight" rating and set a $58.00 price objective (up from $45.00) on shares of Capricor Therapeutics in a research report on Friday, March 13th. Wall Street Zen downgraded Capricor Therapeutics from a "hold" rating to a "sell" rating in a research note on Sunday, January 11th. Finally, Cantor Fitzgerald set a $62.00 target price on Capricor Therapeutics and gave the stock an "overweight" rating in a research report on Friday, March 13th. Nine research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Capricor Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $46.09.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company's leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.